Ochiai T et al. |
Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. |
1991 |
Transplant. Proc. |
pmid:1721255
|
Siekierka JJ et al. |
Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721256
|
Morris RE |
In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. |
1991 |
Transplant. Proc. |
pmid:1721257
|
Kobayashi M et al. |
FK 506 assay past and present--characteristics of FK 506 ELISA. |
1991 |
Transplant. Proc. |
pmid:1721258
|
Müller MK et al. |
Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. |
1991 |
Transplant. Proc. |
pmid:1721286
|
Francavilla A et al. |
The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. |
1991 |
Transplant. Proc. |
pmid:1721287
|
Blanc P et al. |
Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. |
1991 |
Transplant. Proc. |
pmid:1721288
|
Loréal O et al. |
FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. |
1991 |
Transplant. Proc. |
pmid:1721289
|
McCauley J et al. |
Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. |
1991 |
Transplant. Proc. |
pmid:1721290
|
Yagihashi A et al. |
The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721318
|
Woo J et al. |
Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. |
1991 |
Transplant. Proc. |
pmid:1721319
|
Chen-Woan M et al. |
Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721320
|
Fukuzawa M et al. |
Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. |
1991 |
Transplant. Proc. |
pmid:1721321
|
Macleod AM and Thomson AW |
FK 506: an immunosuppressant for the 1990s? |
1991 |
Lancet |
pmid:1702172
|
Alessiani M et al. |
CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721351
|
Green M et al. |
Infectious complications of pediatric liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721352
|
Torre-Cisneros J et al. |
The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721353
|
Paul AA et al. |
CMV retinitis and the use of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721354
|
de Paulis A et al. |
Characterization of the anti-inflammatory effect of FK-506 on human mast cells. |
1991 |
J. Immunol. |
pmid:1721644
|
Jain AB et al. |
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1703354
|
Venkataramanan R et al. |
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1703355
|
Omar G et al. |
FK 506 inhibition of cyclosporine metabolism by human liver microsomes. |
1991 |
Transplant. Proc. |
pmid:1703356
|
Eiras G et al. |
Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. |
1991 |
Transplant. Proc. |
pmid:1703357
|
Moutabarrik A et al. |
FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. |
1991 |
Transplant. Proc. |
pmid:1721382
|
Moutabarrik A et al. |
In vitro FK 506 kidney tubular cell toxicity. |
1991 |
Transplant. Proc. |
pmid:1721383
|
McCauley J et al. |
Changes in renal function after liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1721385
|
Tauxe WN et al. |
A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721386
|
McCauley J et al. |
Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721387
|
Ohtsuka S et al. |
The effect of short-term FK 506 therapy on pancreas transplantation in rats. |
1991 |
Transplant. Proc. |
pmid:1721413
|
Yamashita T et al. |
Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. |
1991 |
Transplant. Proc. |
pmid:1721414
|
Fukuzaki T et al. |
Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. |
1991 |
Transplant. Proc. |
pmid:1721415
|
Tzakis AG et al. |
FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721416
|
Masaoka T et al. |
Phase II study of FK 506 for allogeneic bone marrow transplantation. |
1991 |
Transplant. Proc. |
pmid:1721417
|
Steinmann B et al. |
Mechanism of action of FK 506 and cyclosporin. |
1991 |
Lancet |
pmid:1704088
|
Sewing KF and Christians U |
FK 506. |
1991 |
Lancet |
pmid:1704090
|
Wiederrecht G et al. |
FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1704127
|
Propper DJ et al. |
Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. |
1991 |
Transplant. Proc. |
pmid:1721446
|
Fabrega AJ et al. |
FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. |
1991 |
Transplant. Proc. |
pmid:1721447
|
Davies CB et al. |
Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. |
1991 |
Transplant. Proc. |
pmid:1721448
|
Abu-Elmagd K et al. |
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. |
1991 |
Transplant. Proc. |
pmid:1721449
|
Halloran PF and Madrenas J |
The mechanism of action of cyclosporine: a perspective for the 90's. |
1991 |
Clin. Biochem. |
pmid:1711939
|
Palaszynski EW et al. |
Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. |
1991 |
Clin. Biochem. |
pmid:1711940
|
Shiraki K et al. |
Effect of FK-506 on replication of human cytomegalovirus in vitro. |
1991 |
J. Antibiot. |
pmid:1712008
|
Sigal NH et al. |
Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. |
1991 |
Transplant. Proc. |
pmid:1712132
|
Nielsen JB et al. |
Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. |
1991 |
Biochemistry |
pmid:2043618
|
Ochiai T et al. |
[Immunosuppressive agents--advances of the developmental studies and the mode of action]. |
1991 |
Nippon Rinsho |
pmid:1715926
|
Brizuela L et al. |
Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. |
1991 |
Mol. Cell. Biol. |
pmid:1715022
|
Heitman J et al. |
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. |
1991 |
Science |
pmid:1715094
|
Morris RE |
Rapamycin: FK506's fraternal twin or distant cousin? |
1991 |
Immunol. Today |
pmid:1715165
|
Baumann G et al. |
Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. |
1991 |
New Biol. |
pmid:1715185
|